目的观察代谢综合征(MS)患者血浆颗粒蛋白前体(PGRN)水平变化,并探讨其临床意义。方法依据中国MS诊断标准将118例受试者分为非MS组63例、MS组55例。测量两组腰围(WC)、体质量指数(BMI);用酶联免疫吸附法测定PGRN及白细胞介素6(IL-6),用...目的观察代谢综合征(MS)患者血浆颗粒蛋白前体(PGRN)水平变化,并探讨其临床意义。方法依据中国MS诊断标准将118例受试者分为非MS组63例、MS组55例。测量两组腰围(WC)、体质量指数(BMI);用酶联免疫吸附法测定PGRN及白细胞介素6(IL-6),用全自动生化仪分析检测血脂、丙氨酸转氨酶(ALT)、天门冬氨酸转氨酶(AST)、血肌酐,氧化酶法检测空腹血糖(FPG),化学发光法检测空腹胰岛素(FINS),氧化酶法测定餐后2 h血糖(2 h PG),计算稳态模型评估的胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)。采用Spearman相关分析PGRN与各指标的关系;用多元逐步回归、二分类变量逻辑回归分析PGRN与MS发病的关系。结果 MS组血浆PGRN水平高于非MS组(P<0.05),且MS组含5个代谢危险组分者血浆PGRN水平高于含3~4个代谢危险组分者(P<0.05)。血浆PGRN与WC、BMI、FPG、2 h PG、FINS、HOMA-IR、ALT、IL-6呈正相关(r分别为0.328、0.254、0.201、0.117、0.185、0.394、0.199、0.273,P均<0.05),与HOMA-β呈负相关(r=-0.179,P<0.05)。多元逐步回归、二分类变量逻辑回归分析显示,PGRN是MS发病的影响因素(OR=1.051,P<0.05)。结论MS患者血浆PGRN水平升高,其水平升高提示MS患病风险增大。展开更多
Non-alcoholic fatty liver disease (NAFLD) includes a variety of histological conditions (ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are characterized by an increased fat co...Non-alcoholic fatty liver disease (NAFLD) includes a variety of histological conditions (ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are characterized by an increased fat content within the liver. The accumulation/deposition of fat within the liver is essential for diagnosis of NAFLD and might be associated with alterations in the hepatic and systemic inflammatory state. Although it is still unclear if each histological entity represents a different disease or rather steps of the same disease, inflammatory processes in NAFLD might influence its pathophysiology and prognosis. In particular, non-alcoholic steatohepatitis (the most inflamed condition in NAFLDs, which more frequently evolves towards chronic and serious liver diseases) is characterized by a marked activation of inflammatory cells and the upregulation of several soluble inflammatory mediators. Among several mediators, cytokines and chemokines might play a pivotal active role in NAFLD and are considered as potential therapeutic targets. In this review, we will update evidence from both basic research and clinical studies on the potential role of cytokines and chemokines in the pathophysiology of NAFLD.展开更多
文摘目的观察代谢综合征(MS)患者血浆颗粒蛋白前体(PGRN)水平变化,并探讨其临床意义。方法依据中国MS诊断标准将118例受试者分为非MS组63例、MS组55例。测量两组腰围(WC)、体质量指数(BMI);用酶联免疫吸附法测定PGRN及白细胞介素6(IL-6),用全自动生化仪分析检测血脂、丙氨酸转氨酶(ALT)、天门冬氨酸转氨酶(AST)、血肌酐,氧化酶法检测空腹血糖(FPG),化学发光法检测空腹胰岛素(FINS),氧化酶法测定餐后2 h血糖(2 h PG),计算稳态模型评估的胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)。采用Spearman相关分析PGRN与各指标的关系;用多元逐步回归、二分类变量逻辑回归分析PGRN与MS发病的关系。结果 MS组血浆PGRN水平高于非MS组(P<0.05),且MS组含5个代谢危险组分者血浆PGRN水平高于含3~4个代谢危险组分者(P<0.05)。血浆PGRN与WC、BMI、FPG、2 h PG、FINS、HOMA-IR、ALT、IL-6呈正相关(r分别为0.328、0.254、0.201、0.117、0.185、0.394、0.199、0.273,P均<0.05),与HOMA-β呈负相关(r=-0.179,P<0.05)。多元逐步回归、二分类变量逻辑回归分析显示,PGRN是MS发病的影响因素(OR=1.051,P<0.05)。结论MS患者血浆PGRN水平升高,其水平升高提示MS患病风险增大。
基金Supported by The Swiss National Science Foundation, No. 32003B-134963/1"Sir Jules Thorn Trust Reg" Foundation+4 种基金Gustave and Simone Prévot Foundation to Montecucco FEU FP7 AtheroRemo, No. 201668Swiss National Science Foundation, No. 310030B-133127Novartis FoundationSwiss Heart Foundation to Mach F
文摘Non-alcoholic fatty liver disease (NAFLD) includes a variety of histological conditions (ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are characterized by an increased fat content within the liver. The accumulation/deposition of fat within the liver is essential for diagnosis of NAFLD and might be associated with alterations in the hepatic and systemic inflammatory state. Although it is still unclear if each histological entity represents a different disease or rather steps of the same disease, inflammatory processes in NAFLD might influence its pathophysiology and prognosis. In particular, non-alcoholic steatohepatitis (the most inflamed condition in NAFLDs, which more frequently evolves towards chronic and serious liver diseases) is characterized by a marked activation of inflammatory cells and the upregulation of several soluble inflammatory mediators. Among several mediators, cytokines and chemokines might play a pivotal active role in NAFLD and are considered as potential therapeutic targets. In this review, we will update evidence from both basic research and clinical studies on the potential role of cytokines and chemokines in the pathophysiology of NAFLD.